$20.29+0.22 (+1.10%)
Market open · 15-min delayed · as of 3:49 PM ET
Amneal Pharmaceuticals Inc · Overview
Industry: Drugs · see every company filed here →
Amneal Pharmaceuticals Inc scores 47/100. Mixed. Financial health is the soft spot, trading at 90× earnings versus 400 Healthcare peers.
Tenet Score · vs sector
n=400Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value43
Quality59
Health39
Growth48
Factor grades
Grid rings: 25 · 50 · 75 · 100 percentile
ValueDQualityCHealthDGrowthDMomentumB
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Price
Loading chart…
P/E
90.5×
price ÷ the latest fiscal year EPS
P/B
—
no P/B on file
P/S
2.1×
price to sales
ROE
—
negative equity denominator
Operating margin
13.1%
before interest and tax
Net margin
4.2%
fiscal 2025
Current ratio
2.17
fiscal 2025
Net debt / EBITDA
3.6×Tenet-derived Total debt less cash and short-term investments, over EBITDA (operating income plus depreciation and amortisation) from the filed statements. Long-term investments are not counted as cash. For some companies they include marketable securities held for more than a year. Computed by Tenet from the filed statements (formula house-nde.v1), because the data vendor published no value for this year.
computed by Tenet from the filed statements
EPS CAGR 1y
—
needs five years of positive earnings
Market cap
$6.5B
mid cap
Div yield
—
no yield on file
52-wk range
9.56 – 21.18
low → high
Market cap: share price × the latest quarter's diluted weighted-average share count (vendor).
The whole report, at a glance · every card is a live peek, click any to open the section
Tenets
4 / 17
- ✕ Buffett Quality
- ~ Piotroski F-Score
- ✕ Munger Compounders
- ~ Magic Formula
- ✕ Graham Defensive
- ✕ Quality Compounder
+11 more →
Financials
Revenue, margins and the five-year statements.Analyst Forecasts
Consensus estimates are on the Analyst tab.
Earnings
Report dates and the beat-versus-miss record.Statistics
ROIC14%
Gross margin37%
Technical Analysis
Uptrend short-term signalvs 50-day+9.8%
vs 200-day+34.1%
RSI (14)63
News & Insights
Headlines are on the News tab.Dividends
Pays no dividend. Every dollar of profit is reinvested into the business.Ownership
52% institutional
13F flows & insider trades land here.
About Amneal Pharmaceuticals Inc
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segment…
Composite computed 2026-10-02 · peer basis: Healthcare (n=400) · every glimpse links to its full section with sources · not investment advice.
ETF exposure
Free account: the funds that hold AMRX, and at what weight. Everything else on this page stays open.Create a free account